NCT04357873View on ClinicalTrials.gov

Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

December 15, 2022

Study Completion Date

November 26, 2024

Conditions
Squamous Cell Lung CancerVulvar CancerPenile CancerCervix CancerHead and Neck Squamous Cell CarcinomaAnal Cancer
Interventions
DRUG

pembrolizumab; vorinostat

"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression"

Trial Locations (14)

Unknown

Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers

Institut Bergonié, Bordeaux

Centre François Baclesse, Caen

Centre Jean Perrin, Clermont-Ferrand

Centre George François Leclerc, Dijon

Centre Oscar Lambret, Lille

Centre Léon Bérard, Lyon

Institut de Cancérologie de Lorraine, Nancy

Institut de Cancérologie de l'Ouest (site René Gauducheau), Nantes

Institut Curie, Paris

Centre Hospitalier Lyon Sud - Hospices Civils de Lyon, Pierre-Bénite

Institut Godinot, Reims

Centre Paul Strauss, Strasbourg

Institut Claudius Regaud, Toulouse

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Fondation ARC

OTHER

collaborator

ERA-NET

UNKNOWN

lead

UNICANCER

OTHER

NCT04357873 - Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations | Biotech Hunter | Biotech Hunter